Literature DB >> 23344720

Impact of subcortical white matter lesions on dopamine transporter SPECT.

Elisabeth Funke1, Andreas Kupsch, Ralph Buchert, Winfried Brenner, Michail Plotkin.   

Abstract

Subcortical arteriosclerotic encephalopathy (SAE) can affect the nigrostriatal system and presumably cause vascular parkinsonism (VP). However, in patients with SAE, the differentiation of VP from idiopathic Parkinson's disease (IPS) is challenging. The aim of the present study was to examine the striatal dopamine transporter (DAT) density in patients with parkinsonism and SAE. Fifteen consecutive patients with parkinsonian symptoms displayed SAE, as detected by magnetic resonance imaging (MRI). Fifteen retrospectively chosen, matched patients with diagnosis of IPS without any abnormalities in MRI served as a reference group. DAT SPECT was performed using the tracer ¹²³I-FP-CIT. Scans were acquired on a triple-head SPECT system (Multispect 3, Siemens) and analysed using the investigator-independent BRASS™ software (HERMES). In the SAE group, a DAT deficit was observed in 9/15 patients. In contrast, all patients from the IPS group showed a reduced DAT binding (p = 0.008). The specific binding ratios (BR) of putamen contralateral to the side of the more affected limb versus occipital lobe were in trend higher in patients with SAE versus patients in the IPS-group (p = 0.053). Indices for putaminal asymmetry (p = 0.036) and asymmetry caudate-to-putamen (p = 0.026) as well as the ratio caudate-to-putamen (p = 0.048) were significantly higher in IPS patients having no SAE. DAT deficit was less pronounced in patients with SAE and parkinsonism than in patients with IPS without any abnormalities in the MRI. A potential role of DAT SPECT in the differential diagnosis of VP and IPS requires more assessments within prospective studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23344720     DOI: 10.1007/s00702-013-0977-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  44 in total

Review 1.  Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.

Authors:  Kenneth Marek; Danna Jennings; John Seibyl
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

2.  Relation of cerebral small-vessel disease and brain atrophy to mild Parkinsonism in the elderly.

Authors:  Christiane Reitz; Claudia Trenkwalder; Konrad Kretzschmar; Andreas Roesler; Arnold V Eckardstein; Klaus Berger
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

Review 3.  A new look at levodopa based on the ELLDOPA study.

Authors:  S Fahn
Journal:  J Neural Transm Suppl       Date:  2006

Review 4.  Vascular parkinsonism--an important cause of parkinsonism in older people.

Authors:  Bhomraj Thanvi; Nelson Lo; Tom Robinson
Journal:  Age Ageing       Date:  2005-03       Impact factor: 10.668

5.  Vascular parkinsonism: a distinct, heterogeneous clinical entity.

Authors:  M Demirkiran; H Bozdemir; Y Sarica
Journal:  Acta Neurol Scand       Date:  2001-08       Impact factor: 3.209

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1.

Authors:  K Y Tzen; C S Lu; T C Yen; S P Wey; G Ting
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

8.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.

Authors:  T Brücke; S Asenbaum; W Pirker; S Djamshidian; S Wenger; C Wöber; C Müller; I Podreka
Journal:  J Neural Transm Suppl       Date:  1997

9.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

10.  Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa.

Authors:  H Boecker; A Weindl; K Leenders; A Antonini; T Kuwert; F Kruggel; H Grafin von Einsiedel; B Conrad
Journal:  Acta Neurol Scand       Date:  1996-06       Impact factor: 3.209

View more
  1 in total

Review 1.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.